Zymeworks (NASDAQ:ZYME – Get Free Report) announced that its Board of Directors has initiated a share buyback program on Monday, November 16th, RTT News reports. The company plans to buy back $200 million in shares. This repurchase authorization permits the company to repurchase up to 10.9% of its shares through open market purchases. Share repurchase programs are usually an indication that the company’s board believes its stock is undervalued.
Zymeworks Price Performance
NASDAQ ZYME traded up $0.21 during trading hours on Monday, hitting $26.45. 905,093 shares of the company’s stock traded hands, compared to its average volume of 1,376,009. Zymeworks has a 52-week low of $21.52 and a 52-week high of $31.97. The company has a market capitalization of $1.83 billion, a PE ratio of 50.87 and a beta of 1.32. The firm’s 50-day moving average is $27.26 and its 200-day moving average is $25.50.
Zymeworks (NASDAQ:ZYME – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The company had revenue of $512.92 million during the quarter, compared to the consensus estimate of $227.40 million. During the same quarter in the prior year, the firm earned ($0.26) EPS. Zymeworks’s quarterly revenue was up 828.7% on a year-over-year basis. Equities research analysts predict that Zymeworks will post 1.31 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently commented on the company. Truist Financial boosted their price target on Zymeworks from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. Citizens Jmp increased their price objective on Zymeworks from $32.00 to $39.00 and gave the company a “market outperform” rating in a research note on Friday. JPMorgan Chase & Co. raised their price objective on Zymeworks from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, September 3rd. Wolfe Research assumed coverage on shares of Zymeworks in a research note on Thursday, September 17th. They set an “outperform” rating on the stock. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $52.00 target price on shares of Zymeworks in a report on Friday, October 23rd. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.25.
Read Our Latest Analysis on Zymeworks
Insider Activity at Zymeworks
In related news, EVP Adam Schayowitz sold 13,832 shares of the stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $25.85, for a total value of $357,557.20. Following the completion of the sale, the executive vice president owned 23,205 shares of the company’s stock, valued at approximately $599,849.25. This trade represents a 37.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul Moore sold 39,741 shares of Zymeworks stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $26.07, for a total value of $1,036,047.87. Following the transaction, the insider owned 33,756 shares in the company, valued at approximately $880,018.92. The trade was a 54.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 37.73% of the company’s stock.
Zymeworks Company Profile
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
Read More
- Five stocks we like better than Zymeworks
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
